ArticleScientific reports2025
TGFβ1 accelerated the progression of diabetic nephropathy via up-regulating BRD4/Notch1/YAP signaling induced fibrosis and proliferation in fibroblasts.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction and Validation of a Long-Term Visual Prognosis Prediction Model for Proliferative Diabetic Retinopathy After Vitrectomy Based on Machine Learning.Endocrinology, diabetes & metabolism · 2026Article
- Glycolytic lactylation modulates cell death decisions in diabetic kidney disease: Metabolic‑epigenetic interplay between ferroptosis and autophagy in fibrotic remodeling (Review).International journal of molecular medicine · 2026Review
- Tubular NAT10 Promotes the Secretion of TGF-β and Lactate to Drive Fibroblast Activation in Diabetic Kidney Disease.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence implicates transforming growth factor-β1 (TGF-β1)-mediated renal tubular cell apoptosis in the pathogenesis of diabetic nephropathy. This investigation sought to elucidate the molecular mechanisms governing the pathogenic role of TGF-β1 in diabetic nephropathy progression. In vitro, human renal fibroblasts purchased were divided into six groups after different stimuli. Western blot was used to observe the cell protein expression, and CCK-8 was used to observe cell proliferation. In the in vivo experiment, 32 SD male rats were randomly divided into Control group, Model group, Model + TGFβ1 group, and Model + TGFβ1 + Notch1-KD group, and Model group was experimentally induced by a high-fat diet (HFD)/streptozocin(STZ) regimen in type 2 diabetes mellitus ( T2DM ) mouse model. HE staining was used to observe the degree of renal tissue fibrosis, and Western blot was used to observe the protein expression in renal tissues. In the in vitro experiment, TGFβ1 induced fibrosis and fibroblast proliferation by regulating the BRD4/Notch1/YAP signaling pathway. In the in vivo experiment, it was found that diabetic nephropathy rats treated with TGFβ1 showed significantly increased renal tissue fibrosis; when Notch1 was knocked down, the renal tissue fibrosis in diabetic nephropathy rats was significantly reduced. TGFβ1 accelerates the progression of diabetic nephropathy by inducing fibrosis and fibroblast proliferation through the regulation of the BRD4/Notch1/YAP signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.